Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom

1. Spelman, T.
2. Herring, W.L.
3. Zhang, Y.
4. Tempest, M.
5. Pearson, I.
6. Freudensprung, U.
7. Acosta, C.
8. Dort, T.
9. Hyde, R.
10. Havrdova, E.
11. Horakova, D.
12. Trojano, M.
13. De Luca, G.
14. Lugaresi, A.
15. Izquierdo, G.
16. Grammond, P.
17. Duquette, P.
18. Alroughani, R.
19. Pucci, E.
20. Granella, F.
21. Lechner-Scott, J.
22. Sola, P.
23. Ferraro, D.
24. Grand’Maison, F.
25. Terzi, M.
26. Rozsa, C.
27. Boz, C.
28. Hupperts, R.
29. Van Pesch, V.
30. Oreja-Guevara, C.
31. van der Walt, A.
32. Jokubaitis, V.G.
33. Kalincik, T.
34. Butzkueven, H.
35. Horakova, D.
36. Trojano, M.
37. Luca, G.
38. Lugaresi, A.
39. Izquierdo, G.
40. Pucci, E.
41. Lechner-Scott, J.
42. Sola, P.
43. Butzkueven, H.
44. Show all authors +

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1007/S40273-021-01106-6 GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus